MedPath
NMPA Approval

Rozanolixizumab Injection

国药准字SJ20250012

April 25, 2025

Drug Information

罗泽利昔珠单抗注射液

优迪革

注射剂

280mg(2mL)/支

生物制品

April 25, 2025

March 24, 2030

Company Information

Applicant Company

UCB-Pharma SA

Allée de la Recherche 60, B-1070 Bruxelles, Belgium

Manufacturing Company

Eisenbahnstraße 2 - 4, Langenargen, 88085 Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

罗泽利昔珠单抗注射液 - NMPA 批准文号 | MedPath